Biofrontera Inc.NASDAQ: BFRI

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

· Issued by Biofrontera Inc. via GlobeNewswire

Summary by 6ix AI

Biofrontera Inc., a US skin-care drug company that sells Ameluz gel with the BF-RhodoLED lamp for light-activated treatment of actinic keratosis (rough, scaly sun-damaged skin patches), will report results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.

Key details

  • Management will host a conference call and webcast at 10:00 a.m. Eastern Time on Thursday, August 13, 2026 to discuss the results and give a business update.
  • Dial-in numbers are 1-877-877-1275 (US and Canada toll-free) and 1-412-858-5202 (international); callers should ask to join the Biofrontera call, and the webcast opens approximately 20 minutes before the call starts.

6ix AI wrote this summary from the release below and checked it against the release.

WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.

Management will host a conference call and webcast the same day at 10:00 a.m. Eastern Time to discuss the results and provide a business update.

Conference Call and Webcast Details

Detail

Information

Date

Thursday, August 13, 2026

Time

10:00 a.m. Eastern Time

U.S. / Canada toll-free

1-877-877-1275

International

1-412-858-5202

Webcast

Participants dialing in by telephone should ask to be joined into the Biofrontera call. The webcast will be accessible beginning approximately 20 minutes prior to the start of the call.

About Biofrontera Inc.

Biofrontera Inc. (NASDAQ: BFRI) is a U.S. specialty dermatology company focused on the treatment of dermatological conditions. The Company commercializes Ameluz® (aminolevulinic acid hydrochloride) Gel, 10%, together with the BF-RhodoLED® lamp, for photodynamic therapy (PDT) in the treatment of actinic keratosis. Biofrontera Inc. has been a standalone, publicly traded company since its 2021 IPO and operates a wholly owned subsidiary, Biofrontera Discovery GmbH, in Germany. For more information, visit www.biofrontera-us.com.

Investor Contact

Ben Shamsian
Lytham Partners
[email protected]

Biofrontera Inc. on 6ix

Story so far

Earlier from Biofrontera

Later from Biofrontera

All Biofrontera news releases